At this year’s American Heart Association (AHA) Scientific Sessions, the latest insights from clinical studies were shared to inform high-quality care by cardiologists worldwide. Dr Sheila Hegde and Dr Sara Saberi presented findings from the EXPLORER-HCM Study into the benefits of mavacamten, a first-in-class selective cardiac myosin inhibitor, on the underlying pathophysiology of obstructive hypertrophic cardiomyopathy (HCM). Insights from these poster presentations were outlined in this article.
EMJ Cardiology 9 [Supplement 1] . 2021
January 2021
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/06/Innov-Article-Congenital-Heart-Disease-and-Autism-Spectrum-Disorder-web-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/06/Cardio-Article-Endovascular-Stenting-for-Superior-Vena-Cava-Syndrome-web-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/04/Cardio-12.1-Interview-David-Fischman-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/01/Interview-940x564.png)